Literature DB >> 33582653

A retrospective study of long term follow-up of 2283 vitiligo patients treated by autologous, non-cultured melanocyte-keratinocyte transplantation.

Dimin Zhang1, Xiaodong Wei1, Weisong Hong1, Lifang Fu1, Guopei Qian1, Ai-E Xu1.   

Abstract

BACKGROUND: Autologous non-cultured melanocyte-keratinocyte transplantation (MKTP) can be used to treat stable vitiligo cases, but there were insufficient clinical data to evaluate its safety and efficacy.
OBJECTIVE: To assess the influence of various factors on the therapeutic outcome of MKTP.
METHOD: The single-center retrospective study included stable vitiligo patients who underwent MKTP between June 2009 and June 2018. Univariate and/or multivariable analysis were used to determine the factors affecting the outcome of repigmentation. RESULT: The study comprised 2283 patients who had long-term follow-up data (12-108months). Excellent repigmentation was achieved in 400/606 (66%),788/1341 (58.8%),437/684 (63.9%),18/24 (75%) patients with segmental vitiligo, pre-MKTP phototherapy, younger than 24 years, the lesion on the perineum and scrotum, respectively. However, the patients with a positive family history, Koebner phenomenon responded worse(χ2=29.417, P<0.001; χ2=107.397, P<0.001; respectively). Overall, a significant positive correlation between duration of stability and percentage of repigmentation was found (χ2=42.053, P<0. 001).
CONCLUSION: MKTP is efficient and well tolerated for stable vitiligo treatment. Various factors such as duration of disease stability, vitiligo type, family history, site of lesion should be carefully assessed before using MKTP, as it would further improve the post-operative repigmentation.

Entities:  

Keywords:  non-cultured melanocyte-keratinocyte transplantation; vitiligo

Mesh:

Year:  2021        PMID: 33582653      PMCID: PMC7950304          DOI: 10.18632/aging.202472

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  45 in total

1.  Vitiligo is not a cosmetic disease.

Authors:  Khaled Ezzedine; Vaneeta Sheth; Michelle Rodrigues; Viktoria Eleftheriadou; John E Harris; Iltefat H Hamzavi; Amit G Pandya
Journal:  J Am Acad Dermatol       Date:  2015-11       Impact factor: 11.527

Review 2.  Medical and Maintenance Treatments for Vitiligo.

Authors:  Thierry Passeron
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

3.  A randomized controlled study of the effects of different modalities of narrow-band ultraviolet B therapy on the outcome of cultured autologous melanocytes transplantation in treating vitiligo.

Authors:  Di-min Zhang; Wei-song Hong; Li-fang Fu; Xiao-dong Wei; Ai-e Xu
Journal:  Dermatol Surg       Date:  2014-01-21       Impact factor: 3.398

4.  Treatment of vitiligo with a melanocyte-keratinocyte cell suspension versus dermabrasion only: a pilot study with a 12-month follow up.

Authors:  Osvaldo Tomás Vázquez-Martínez; Herminia G Martínez-Rodríguez; Leobardo Velásquez-Arenas; Dolores Baños-González; Rocío Ortíz-López; Gerardo Padilla-Rivas; Oliverio Welsh; Jorge Ocampo-Candiani
Journal:  J Drugs Dermatol       Date:  2011-09       Impact factor: 2.114

Review 5.  Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata.

Authors:  Chauncey C Barbulescu; Nathaniel B Goldstein; Dennis R Roop; David A Norris; Stanca A Birlea
Journal:  J Invest Dermatol       Date:  2019-06-10       Impact factor: 8.551

6.  Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation.

Authors:  S Altalhab; M I AlJasser; S V Mulekar; A Al Issa; S Mulekar; J Diaz; A Diallo; K Ezzedine
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-02-22       Impact factor: 6.166

7.  Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus.

Authors:  N van Geel; E Wallaeys; B K Goh; M De Mil; J Lambert
Journal:  Br J Dermatol       Date:  2010-12       Impact factor: 9.302

8.  Blister roof grafting, cultured melanocytes transplantation and non-cultured epidermal cell suspension transplantation in treating stable vitiligo: A mutual self-control study.

Authors:  Huaye Bao; Weisong Hong; Lifang Fu; Xiaodong Wei; Guopei Qian; Aie Xu
Journal:  J Dermatolog Treat       Date:  2015-08-06       Impact factor: 3.359

9.  Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo.

Authors:  Mariana Gontijo Ramos; Daniel Gontijo Ramos; Camila Gontijo Ramos
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

Review 10.  Autologous non-cultured melanocyte-keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives.

Authors:  Dalia Bassiouny; Samia Esmat
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-10-26
View more
  2 in total

Review 1.  Surgical Treatment of Vitiligo.

Authors:  Alicja Frączek; Marta Kasprowicz-Furmańczyk; Waldemar Placek; Agnieszka Owczarczyk-Saczonek
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 4.614

2.  Inhibition of Fam114A1 protects melanocytes from apoptosis through higher RACK1 expression.

Authors:  Miaoni Zhou; Fuquan Lin; Xingang Wu; Zhuyi Ping; Wen Xu; Rong Jin; Aie Xu
Journal:  Aging (Albany NY)       Date:  2021-11-27       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.